0001209191-21-050256.txt : 20210806
0001209191-21-050256.hdr.sgml : 20210806
20210806200029
ACCESSION NUMBER: 0001209191-21-050256
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210804
FILED AS OF DATE: 20210806
DATE AS OF CHANGE: 20210806
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kulkarni Samarth
CENTRAL INDEX KEY: 0001682019
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 211154315
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-04
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682019
Kulkarni Samarth
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
1
1
0
0
Chief Executive Officer
Common Shares
2021-08-04
4
M
0
1500
12.57
A
189219
D
Common Shares
2021-08-04
4
S
0
1500
125.02
D
187719
D
Common Stock
2021-08-05
4
M
0
28500
12.57
A
216219
D
Common Stock
2021-08-05
4
S
0
1000
126.67
D
215219
D
Common Stock
2021-08-05
4
S
0
4700
127.82
D
210519
D
Common Stock
2021-08-05
4
S
0
13499
128.85
D
197020
D
Common Stock
2021-08-05
4
S
0
6819
129.82
D
190201
D
Common Stock
2021-08-05
4
S
0
2482
130.51
D
187719
D
Stock Option (Right to Buy)
12.57
2021-08-04
4
M
0
1500
0.00
D
2026-07-15
Common Shares
30000
61833
D
Stock Option (Right to Buy)
12.57
2021-08-05
4
M
0
28500
0.00
D
2026-07-15
Common Stock
28500
33333
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.33 to $127.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.37 to $128.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.37 to $129.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.38 to $130.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.38 to $130.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
/s/ Michael Esposito, attorney-in-fact
2021-08-06